Safety and efficacy of nimotuzumab combined with chemoradiotherapy in Chinese patients with locally advanced cervical cancer

尼妥珠单抗 医学 宫颈癌 内科学 实体瘤疗效评价标准 放化疗 肿瘤科 进行性疾病 临床研究阶段 临床终点 化疗 吉西他滨 放射治疗 癌症 粘膜炎 顺铂 外科 临床试验 表皮生长因子受体
作者
Yongfa Chen,Wu-bin Tang,Xin-xi pan,Chu-rong Wu,Yang Cao,Wen Yang
出处
期刊:OncoTargets and Therapy [Dove Medical Press]
卷期号:Volume 10: 4113-4119 被引量:12
标识
DOI:10.2147/ott.s133756
摘要

Objective: To evaluate efficacy and safety of nimotuzumab combined with chemotherapy and radiotherapy in women with locally advanced cervical cancer. Materials and methods: Women with locally advanced cervical cancer (stage IIB, III, or IVA) who experienced relapse after first-line chemoradiotherapy and one or more lines of palliative chemotherapy were enrolled. All patients received nimotuzumab weekly at 200 mg/m 2 as single agent for 4 weeks (induction phase), then concurrent with 6 cycles (21-day per cycle) of gemcitabine (800 mg/m 2 ) or cisplatin (50 mg/m 2 ) for 18 weeks (concurrent phase) and then once every 2 weeks (maintenance phase). Overall response rate (ORR) was assessed after 4 weeks of induction therapy and then every 3 months according to response evaluation criteria in solid tumors version 1.1 (primary end point). Secondary end points include progression-free survival (PFS), overall survival (OS), and drug toxicity. Descriptive statistics was used for ORR, and Kaplan–Meier curves were generated for OS and PFS. Results: A total of 80 women with locally advanced cervical cancer were enrolled and evaluated for safety and efficacy. Our results demonstrated that none of the patients had a complete response (0%), 11 patients had a partial response (14%), and 10 patients had progressive disease (13%), giving a tumor response rate of 14%. A total of 59 patients had stable disease (74%), giving a disease control rate of 88% (70/80). Median PFS was 8.21 months (95% confidence interval [CI]: 5.09–12.45). Median OS was 11.96 months (95% CI: 8.11–23.95). The most common adverse events were mucositis, myelosuppression, and gastrointestinal disturbance. Conclusion: Our study results suggested that nimotuzumab in combination with chemotherapy and radiotherapy is well tolerated, and could be a better treatment alternative in patients with locally advanced cervical cancer. Keywords: nimotuzumab, metastatic cervical cancer, Chinese patients, radiotherapy, chemoradiotherapy
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lt0217完成签到,获得积分10
1秒前
多边形完成签到 ,获得积分10
3秒前
77小姐完成签到 ,获得积分10
4秒前
俭朴映寒完成签到,获得积分10
8秒前
Sweety_完成签到 ,获得积分10
8秒前
柒柒球完成签到 ,获得积分10
9秒前
小川完成签到 ,获得积分10
9秒前
冷傲的孤晴完成签到,获得积分10
10秒前
10秒前
千柳完成签到 ,获得积分10
11秒前
Pigmentuman完成签到,获得积分10
12秒前
xyzlancet完成签到,获得积分10
20秒前
yalin完成签到,获得积分10
24秒前
云峤完成签到 ,获得积分10
25秒前
Astoria完成签到,获得积分10
32秒前
shishuang完成签到,获得积分10
33秒前
暮晓见完成签到 ,获得积分10
33秒前
小金鱼8569完成签到,获得积分10
35秒前
懒羊羊完成签到 ,获得积分10
38秒前
川川贝贝宝完成签到 ,获得积分10
39秒前
kiterunner完成签到,获得积分10
40秒前
圆1223完成签到 ,获得积分10
41秒前
荣幸完成签到 ,获得积分10
41秒前
小金鱼8569完成签到,获得积分10
45秒前
随心所欲完成签到 ,获得积分0
45秒前
苗条的白梅完成签到,获得积分10
45秒前
xybjt完成签到 ,获得积分10
47秒前
大呲花完成签到,获得积分10
51秒前
成就苞络完成签到,获得积分10
53秒前
w0r1d完成签到 ,获得积分10
53秒前
xiaojinyu195完成签到,获得积分10
55秒前
xiaojinyu131完成签到,获得积分10
1分钟前
Connie425完成签到 ,获得积分10
1分钟前
alixy完成签到,获得积分10
1分钟前
萌萌2完成签到,获得积分10
1分钟前
爱沉淀的太阳花完成签到,获得积分10
1分钟前
1分钟前
xiaoxiao完成签到 ,获得积分10
1分钟前
LingMg完成签到 ,获得积分10
1分钟前
丰富的澜完成签到 ,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180068
求助须知:如何正确求助?哪些是违规求助? 9570224
关于积分的说明 21808724
捐赠科研通 7776054
什么是DOI,文献DOI怎么找? 3433261
关于科研通互助平台的介绍 2557425
邀请新用户注册赠送积分活动 2479012